Human Th1/Th2 Luminex® Performance Assay 13-plex Fixed Panel LKTM008B from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman Th1/Th2 Luminex® Performance Assay 13-plex Fixed Panel
CompanyR&D Systems, a Bio-Techne Brand
Price $3,490.00Supplier Page View Company Product Page
Catalog NumberLKTM008B
Quantity1 Kit
ApplicationsLuminex
ReactivityHuman
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
NCBI Full Gene Namecolony stimulating factor 2
NCBI Gene AliasesCSF, GMCSF

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) High Schistosoma mansoni infection intensity is associated with distinct gut microbiota and low levels of systemic cytokines in children along the Albert-Nile, Northern UgandaBMC microbiologyAugust 14, 2025Mulindwa J, Lujumba I, Musiime C, Namulondo J, Kimuda MP, Nyangiri O, Cuu G, Mwubaha C, Tukwasibwe S, Ssemaganda A, et al.(TNFA, TNFB) were quantified using the Human Th1/Th2 Luminex bead-based assay (R&D Systems, Cat No. LKTM008B) on the Magpix- Milliplex map System (Luminex technologies). The experimental protocol was carried out

(2) Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires interferon-alphaClinical Cancer ResearchJuly 1, 2025Els M.E. Verdegaal, Anique L.C. Verpoorte, Monique K. van der Kooij, Linda de Bruin, Marten Visser, Caroline E. van der Minne, Vera Weeda, Inge C.F.M. Roozen, Mare A. Jonker, Inge M. Westra, et al.was determined using the 13-plex human Th1/Th2 fixed panel Luminex assay (R&D Systems, cat. number. LKTM008B) according to the manufacturer’s instructions. The proliferation during the pre-REP phase and during

(3) Effective TIL Therapy for Patients with Checkpoint-Resistant Melanoma without Lymphodepleting Regimens Requires IFNαClin Cancer ResMay 6, 2025Els M.E. Verdegaal, Anique L.C. Verpoorte, Monique K. van der Kooij, Linda de Bruin, Marten Visser, Caroline E. van der Minne, Vera Weeda, Inge C.F.M. Roozen, Mare A. Jonker, Inge M. Westra, et al.was determined using the 13-plex human Th1/Th2 fixed panel Luminex assay (R&D Systems, cat. number. LKTM008B) according to the manufacturer’s instructions. The proliferation during the pre-REP phase and during

(4) IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activityNature communicationsJanuary 2, 2024Landoni E, Woodcock MG, Barragan G, Casirati G, Cinella V, Stucchi S, Flick LM, Withers TA, Hudson H, Casorati G, et al.

Be the First to Write a Review!

Human Th1/Th2 Luminex® Performance Assay 13-plex Fixed Panel

Human Th1/Th2 Luminex® Performance Assay 13-plex Fixed Panel from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (4)

Reviews

Human Th1/Th2 Luminex® Performance Assay 13-plex Fixed Panel from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map